Profluent is looking for an Executive Director / Vice President to lead the scientific strategy for their gene editing therapeutic portfolio, focusing on liver-directed customized base editing for severe inborn metabolic diseases. The role involves overseeing translational biology and in vivo pharmacology, managing cross-functional therapeutic programs, and collaborating with various teams to generate data packages for development candidates. The ideal candidate will have extensive experience in genetic medicines and a strong understanding of liver biology and metabolic diseases.
See how your résumé matches this role — and tailor it from what actually gets interviews.